* Internat
:PROPERTIES:
:CATEGORY: internat
:END:
** InterCHU Grenoble mai 2024
:PROPERTIES:
:CATEGORY: interchu
:END:
*** DONE Visio Julien Theveno
CLOSED: [2023-07-21 Fri 17:54] DEADLINE: <2023-07-21 Fri>
- pas en clinique mais soit Auragen, soit labo de cyto (Pr Coutton) pour avoir un stage de labo
- Ok pour accueillir mai 2024
- th√©matique
  - bioinformatique avec projet √† d√©finir sur des am√©liorations non urgentes +/- publi
    - soit appel de variants difficile
    - soit bionano (en cours)
  - diagnostic : 2-3 g√©nomes √† lire par semaine
- pr√©ciser le sujet avec bioinformaticienne (Virgine ??)
- nombreuses demandes d'interCHU au semestre dernier mais personne pour les 2 prochains (interpr√©tation ailleurs)
- se d√©roulera au CHU de grenoble (p√¥le m√®re-enfant) dans tous les cas

*Julien Thevenon non disponible en ao√ªt*
2 stages √† Lyon pour Auragen =
- interpr√©tation onco
- extraction ADN + s√©quencage
Grenoble = la partie bioinfo
*** DONE Mail coordonateur DES biologie m√©dicale Grenoble pour pr√©ciser
CLOSED: [2023-07-21 Fri 17:54] SCHEDULED: <2023-07-21 Fri>
*** TODO Dossier √† compl√©ter
SCHEDULED: <2023-08-17 Thu>
*** TODO Vision Julien Thevenon + Virginie ?? (bionfo)
** DONE Copie carte d'identi√© + mutuelle accueil h√¥pital
CLOSED: [2023-08-19 Sat 20:09] SCHEDULED: <2023-08-17 Thu>
/Entered on/ [2023-08-08 Tue 21:18]
* Recherche
:PROPERTIES:
:CATEGORY: recherche
:END:
** WDR45
:PROPERTIES:
:CATEGORY: wdr45
:END:
*** DONE Mail Dr Adang pour d√©tails collaboration
SCHEDULED: <2022-08-06 Sat>
Envoy√© <2022-07-22 Fri>
Pas de r√©ponse
*** DONE Donner la r√©ponse √† Chlo√© + Patricia Fergelot
*** TODO appel √† collaboration avec Chlo√©
**** WAIT Questionnaire
***** DONE v0.1
CLOSED: [2022-12-03 Sat 12:35] SCHEDULED: <2022-10-01 Sat>
envoy√© le <2022-10-11 Tue>
** NF1
:PROPERTIES:
:CATEGORY: nf1
:END:
*** Notes
**** Cancers sans double hits ?
Genereviews: /NF1/ somatiques sans clinique NF1
- D'Angelo et al 2019: gliome https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857804/
  #+begin_quote
 As expected, we found that multiple clones for each tumor contained only the germline or somatic mutation, indicating that the two mutations reside on different alleles
  #+end_quote

- Eoli et al 2019: revue cancer neuro : biallelic inactivation is "critical"
- Dunnett-Kane et al 2020: contre-exemple : mutation somatique /NF1/ dans m√©lanome et ad√©nocarcinome pulmonaire mais pas de pr√©disposition !
- Fisher et al 2021: gliome (voir single-hit)

Liste des tumeurs somatiques : pas d‚Äôh√©patoblastome (Philpot2017 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5480124/)

***** Double hit
" the majority of NF1-associated tumours exhibit biallelic inactivation of NF1 [9, 10]."

[10] = knudson
[9] = brehms2009:
| Non nervous           | Gastrointestinal stromal tumour          | Second hit NF1 and some copy number alterations [15]                                              |
|                       | Somatostatinoma                          | ?                                                                                                 |
|                       | Phaeochromocytoma                        | Second hit NF1 [16-18]                                                                            |
|                       | Breast cancer                            | ?                                                                                                 |
|                       | Rhabdomyosarcoma                         | ?                                                                                                 |
|-----------------------+------------------------------------------+---------------------------------------------------------------------------------------------------|
| Nervous system tumour | Astrocytoma                              | Second hit NF1, mutation in TP53, deletion of CDKN2A                                              |
|                       | Malignant peripheral nerve-sheath tumour | Second hit NF1, multiple copy number alterations, mutation in TP53, deletion of CDKN2A [24,25-27] |
|                       | Neuroblastoma                            | Second hit NF1, amplification of MYCN, deletion of 1p36 [28,29]                                   |


Loss of heterozygosity of the NF1 region has been identified in phaeochromocytomas from patients with NF1.16,17 Bausch and colleagues18 noted somatic loss of the non-mutated NF1 allele in 67% of phaeochromocytomas in patients with NF1 with an identified germline mutation.

- Pour les gliomes, double hit :https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857804/ -> "As expected, we found that multiple clones for each tumor contained only the germline or somatic mutation, indicating that the two mutations reside on different alleles"


***** Single hit
Gliome : Fischer2021 https://doi.org/10.1007/s00401-021-02276:
majorit√© ont du double hit mais
#+begin_quote
a somatic abnormality in the second NF1 allele was not found in 3 samples (two with FGFR1 + PIK3CA mutations, one with a MYB:QKI alteration). This suggests that in rare cases, glioma pathogenesis in the context of NF1 may not dependent on loss of the second NF1 allele, as reported for a young adult with NF1 and a malignant glioma [30]
#+end_quote

La r√©f√©rence pointe vers Wong2019 93:1-3. doi:10.1212/WNL.0000000000008623 avec autopsy + philogeny pour ordre des variations
#+begin_quote
This molecular ontology analysis provides a proof-of-concept demonstration that some gliomagenesis-associated events (i.e., KMT2B mutation/amplification) occur before NF1 biallelic inactivation and may be sufficient to drive gliomagenesis in an NF1 heterozygous backgroun
#+end_quote
**** notre patiente
- mutations drivers : CTNNB1, TERT et gain de m√©thylation 11p15 retrouv√© dans [cite:@hirsch2021]
- 1 mutation NF1 constit retrouv√©e en somatique (tumeur + m√©tastase)
  - [[https://genome.ucsc.edu/cgi-bin/hgTracks?db=hg38&lastVirtModeType=default&lastVirtModeExtraState=&virtModeType=default&virtMode=0&nonVirtPosition=&position=chr17%3A31230268%2D31230268&hgsid=1418628939_u4ASAyqv2xSI3YwznwQRfOaGJo4t][NM_001042492.3(NF1):c.2999G>C (p.Arg1000Pro)]] probablement patho
  - mais pas de double hit (une seule all√®le)
  - + variant intronique mais sans anomalie RNAseq et classe 2 clinvar
    NM_001042492.3(NF1):c.6147+8 ?>?
**** Mutation NF1
Rare ?
  - non pr√©sent gnomAD
  - rapport√©e 1x clinvar VOUS
  - au m√™me endroit mais autres fauxsense
    - G>A (p.Arg1000His) = clinvar VOUS x2
    - G>T (p.Arg1000Leu) = clinvar VOUS x2 dont 1 callis√© comme "pr√©disposition au cancer h√©r√©ditaire" sans plus de pr√©cisions
  - le faux sens √† c√¥t√© est bien connu c.2998C>T (p.R1000C) : 3 soumission clinvar et plusieurs article
PMID: 33563663, 27838393, 25074460, 31645765, 29636988, 30476936, 21520333, 29489754
  - synonyme T>C est clinvar b√©nin
  - frameshift  c.2998_2999del (p.Arg1000fs) prenant cette base est rapport√© 2x clinvar classe 4

Onco ? non rapport√© dans cosmic *mais* c.2998C>T (p.R1000C) est rapport√©e
    - dans le foie : homme de 48A
    - sur la peau : Desmoplastic melanoma (publi√© dans PMID 26343386,
      - [[https://pubmed.ncbi.nlm.nih.gov/26343386/][PMID 26343386]]
      - [[https://pubmed.ncbi.nlm.nih.gov/28481359/][PMID 28481359]] -> touche [[https://www.wikipathways.org/index.php/Pathway:WP382][voie MAPK]]
  cosmic : 498 mutations somatique foie + NF1
- interaction possible avec autres mutation ? pas sur le m√™me chromosome...

**** Autres cancers atypiques avec NF1 ? (hotspot, voie MAPK impliqu√©e)
Voir notes de [cite:@landry2021]
**** 2 autres mutation NF1 somatique chez Hirsch
NF1 driver possible selon leur crit√®re : \ge 2 patients
et p<-value < 0.05 avec MutSigCV et Oncodrive

monoall√©lique -> inactivation partielle pourrait jouer un r√¥le
  - NM_001042492.3(NF1):c.350T>G (p.Ile117Ser) retrouv√©e 2x chez un patient
    - non rapport√© dans cosmic
  - NM_001042492.3(NF1):c.5991G>A (p.Trp1997Ter)
    - cosmic : rapport√© dans pheochromocytome x1 et pheochromocytome x1 (patho)

*** T√¢ches
**** DONE Biblio
***** DONE article T. Hirsch
CLOSED: [2022-11-27 Sun 11:28]
***** DONE Autre case report NF1 + h√©patoblastome ?
CLOSED: [2022-11-27 Sun 11:28]
[cite:@dubbink2018]: 1 patient NF1 + mutation somatique /CNNTB1/
[cite:@seminog2012] √©tude √©pid√©mio : surrisque de cancer du foie chez patient NF1 (cf note)
[cite:@ucar2007] 1 cas de NF1 avec h√©patoblastome sans confirmation mol√©culaire
[cite:@landry2021]: √©pid√©mio r√©cente : pas de cas rapport√© NF1 + foie
[cite:@varan2015]: √©pid√©mio plus ancienne : idem
[cite:@skoczen2019] h√©patoblastome + neuroblastome avec plusieurs variants dont NF1
***** DONE NF1 + autres cancers
CLOSED: [2022-11-27 Sun 11:28]
***** DONE Pathway
CLOSED: [2022-11-27 Sun 11:28]
Wnt/Œ≤-cateninng : impliqu√© dans NF1
activation Ras/MAPk -> augemantation niveau de Œ≤catenine

- [cite:@watson2013] : activation de la voie -> d√©veloppement + progression des tumeurs nerveues p√©riph√©riques
  [rappel : entraine des neurofibromes qui sont b√©nin mais qui peuvent se transformer en tumeur maligne]. Mod√®le murin + √©tude de l'expression murine model : activation ->  (activation)
- [cite:@luscan2014] : idem, le plus convaincant, activation de la voie dans MPNSTS
-  In Neurofibromatosis type 1, GTPase function is ablated leading to unsuppressed activation of
the Ras/MAPK signaling pathway[19], which can lead to enhanced Wnt/Œ≤-catenin signaling through
quenching GSK-3Œ≤‚Äôs inhibitory effect on Wnt/Œ≤-catenin signaling[20]
- lien avec ossification
  - sourics avec d√©faut /NF1/ : augmentation niveau de Œ≤catenine sur phase pr√©coce de consolidation fracture osseuse
  - n√©fopam (inhibe Œ≤catenin) : am√©liore ossification [cite:@baht2017] sur de courtes p√©riode de temps
  - idem mais sur souris ag·∫øes et dans Nature (mais sans NF1, juste confirme le lien) [cite:@kwak2019]

  https://www.sciencedirect.com/science/article/pii/S8756328217300571?casa_token=hXS_Cmtozt8AAAAA:enMW1d09t-ms-mlCC6eMIX-C2XyvxuastFwmLi8wkYVO3zZlDdEtSY1eU-7s27xcHLoNe3hrXCM
  (cf leur biblio)

 mini review phttps://www.ijpmonline.org/article.asp?issn=0377-4929;year=2020;volume=63;issue=1;spage=112;epage=115;aulast=Ghose#ref9

- h√©patoblastome selon [cite:@dubbink2018]    (perte de fonction -> exc√®s Œ≤-catening par absence de d√©gradation)

NF2
- [cite:@kim2016] activation
- schwannomees NF2 via hyperactivation  https://www.nature.com/articles/cdd201654
  et vestibular schwanoma
  https://www.nature.com/articles/s41401-022-00908-4
***** Autres
[cite:@kappler2010]: rien ne correspond
Voie RAS impliqu√©e dans h√©patoblastome ?
Possible selon https://pubmed.ncbi.nlm.nih.gov/19665249/
https://www.nature.com/articles/labinvest2016142
**** KILL Trouver autres cas ?
CLOSED: [2022-12-04 Sun 22:13]
***** KILL Appel ANDDI rares
CLOSED: [2022-12-04 Sun 22:13]
***** KILL Appel ITACA
CLOSED: [2022-12-04 Sun 22:13]
**** DONE Plan de l‚Äôarticle
CLOSED: [2022-10-22 Sat 23:33] DEADLINE: <2022-09-17 Sat>
**** DONE Poster v0.1
CLOSED: [2022-11-27 Sun 11:28]
**** TODO Article
***** DONE v0.1
CLOSED: [2022-12-04 Sun 22:13]
***** DONE Corrections v0.2
CLOSED: [2023-03-20 lun. 14:29]
***** DONE Version valid√©e par paul v0.2.7
CLOSED: [2023-03-20 lun. 14:30]
***** DONE Correction Hirsch + Vidau
CLOSED: [2023-06-11 Sun 18:39] SCHEDULED: <2023-05-28 Sun>
***** DONE Derni√®res correction JP
CLOSED: [2023-07-02 Sun 10:52] SCHEDULED: <2023-06-11 Sun>
***** DONE Relancer avant soumission
CLOSED: [2023-07-21 Fri 17:46] SCHEDULED: <2023-07-16 Sun>
**** TODO Soumission
***** Notes
  List journaux acceptant case reports
  https://static1.squarespace.com/static/5db7b349364ff063a6c58ab8/t/6071fb065173800a11ccd0a2/1618082566620/Case+Report+Journals+2020.pdf

- Acad Pediatr : non, scope inad√©quat
- BMC Pediatrics ? trop cher (2 290‚Ç¨) Impact factor 2.1
- Curr Opin Pediatr : il faut √™tre invit√©
- Front Pediatr : 2000$ case report
https://www.frontiersin.org/journals/pediatrics/for-authors/publishing-fees
- Ital J Pediatr : trop cher (cf bmc)
- J Pediatr Health Care : out of scope
- J Pediatr Hematol Oncol Nurs : out of scope
- Minerva Pediatr : gratuit si soumission pas en open access
https://www.minervamedica.it/en/journals/minerva-pediatrics/notice-to-authors.php
  #+begin_quote
 hybrid journal which publishes scientific papers on pediatrics, neonatology, adolescent medicine, child and adolescent psychiatry and pediatric surgery
  #+end_quote
  case report pour la forme de lettres √† l‚Äô√©diteur apparement
  https://www.minervamedica.it/en/journals/minerva-pediatrics/article.php?cod=R15Y2021N05A0467
  #+begin_quote
Subscription-based model
Page charges. Publication of the manuscript is free of charge. Language revision and excessive alterations to proofs will be charged to the authors.
  #+end_quote

- Pediatr Clin North Am : out of scope
- Pediatr Dev Pathol : gratuit
  Case report ok :
#+begin_quote
The Journal covers the spectrum of disorders of early development (including embryology, placentology, and teratology), gestational and perinatal diseases, and all diseases of childhood. Studies may be in any field of experimental, anatomic, or clinical pathology, including molecular pathology. Case reports are published only if they provide new insights into disease mechanisms or new information.
#+end_quote
https://journals.sagepub.com/author-instructions/PDP
#+begin_quote
There are no fees payable to submit to or publish in this journal.
#+end_quote

- Pediatr Hematol Oncol : gratuit
  scope limite :
  #+begin_quote
aim to define optimal therapeutic strategies for children and young adults with cancer and blood disorders.
  #+end_quote

  Case report ok :
  #+begin_quote
  PHO will consider exceptional case studies and case series. These submissions must illuminate novel biological or clinical understanding of cancer or blood diseases must be submitted in the identical format as a letter to the editorial
  #+end_quote

#+begin_quote
 Authors of accepted peer-reviewed articles have the choice to pay a fee to allow perpetual unrestricted online access to their published article to readers globally, immediately upon publication. Authors may take advantage of the open access option at the point of submission. Please note that this choice has no influence on the peer review and acceptance process. These articles are subject to the journal's standard peer-review process and will be accepted or rejected based on their own merit.

The article processing charge (APC) is charged on acceptance of the article and should be paid within 30 days by the author, funding agency or institution. Payment must be processed for the article to be published
#+end_quote
https://www.tandfonline.com/action/authorSubmission?show=instructions&journalCode=ipho20#oa
#+begin_quote
There are no submission fees, publication fees or page charges for this journal.
#+end_quote
***** DONE Soumission AJMG
CLOSED: [2023-07-30 Sun 14:50] SCHEDULED: <2023-07-26 Wed>
****** DONE Figures > 2 en Supplementary
CLOSED: [2023-07-27 Thu 23:31] DEADLINE: <2023-07-24 Mon>
****** DONE V√©rifier citation format APA
CLOSED: [2023-07-27 Thu 23:31] DEADLINE: <2023-07-24 Mon>
****** DONE Ajouter le consentement dans les m√©thodes
CLOSED: [2023-07-27 Thu 23:31] DEADLINE: <2023-07-24 Mon>
****** DONE Rajouter la machine avec s√©quencage
CLOSED: [2023-07-27 Thu 23:31] DEADLINE: <2023-07-24 Mon>
****** DONE Cover letter
CLOSED: [2023-07-27 Thu 23:31] DEADLINE: <2023-07-26 Wed>
https://www.springer.com/gp/authors-editors/authorandreviewertutorials/submitting-to-a-journal-and-peer-review/cover-letters/10285574

#    If known, address the editor who will be assessing your manuscript by their name. Include the date of submission and the journal you are submitting to.
Dear Editor,

#    First paragraph: include the title of your manuscript and the type of manuscript it is (e.g. review, research, case study). Then briefly explain the background to your study, the question you sought out to answer and why.
We would like submit to American Journal of Medical Genetics (part A) a novel
case report entitled "Hepatoblastoma in a patient with Neurofibromatosis type 1:
a case report" to the  for consideration of publication.  Even though a large
variety of tumours have been reported in neurofibromatosis type 1, this is, to
our knowledge, only the third case in medical litterature linked with
hepatoblastoma and the first with germline and somatic molecular analysis.

Following-up the discovery of a liver mass in a 11-year old girl, epithelial
hepatoblastoma with pulmonary metastasis was diagnosed. Germline and somatic
molecular analysis showed classical driver variant for hepatoblastoma and a
germline class 4 /NF1/ variant also found in the tumour. We discuss potential
causal link between the two.

#    Third paragraph: here you should indicate why the readers of the journal #would be interested in the work.
# biological and medical aspects of genetic disorders and birth defects, as well as in-depth documentation of phenotype analysis within the current context of genotype/phenotype correlations.
To facilitate early detection of rare cancers like hepatoblastoma, reporting
such associations is important to increase clinical awareness and improve
follow-up of /NF1/ patients. It also highlights the difficulty of genetic
counseling with aggressive tumours and genetic diseases in the same family.

Thank you for considering our case report for publication.

Sincerely,
****** DONE Soumission initiale
CLOSED: [2023-07-27 Thu 23:31]

** Apprendre le machine learning
:PROPERTIES:
:CATEGORY: machine learning
:END:
[[https://www.reddit.com/r/MachineLearning/comments/5z8110/d_a_super_harsh_guide_to_machine_learning/][Source: reddit]]
*** STRT [[file:books.org::*The elements of statistical learning (217)][The elements of statistical learning (217)]] :
**** STRT Chap 1-4
**** Chap 7-8
*** Introduction to statistical learning
Plus facile, √† faire avant Elements... ?
*** [[https://www.coursera.org/learn/machine-learning/home/info][Andrew NG coursera]]
*** The Deep Learning Book: https://www.deeplearningbook.org/front_matter.pdf
*** Put tensor flow or torch on a linux box and run examples: http://cs231n.github.io/aws-tutorial/
*** Autres cours en lignes
**** https://mlcourse.ai/book/index.html
**** https://www.fast.ai/

* G√©n√©tique
** Coll√®ge [0/32]
*** 1. Architecture du g√©nome
*** 2. Structure et fonction du g√©nome humains: chromosomes sexuels
*** 3. Structure et fonction du g√©nome humains
*** 4. H√©r√©dit√© mend√©lienne
*** 5. G√©n√©tique des populations
*** 6. Cytog√©n√©tique conventionnelle
*** 7. Cytog√©n√©tique mol√©culaire
*** 8. Anomalies h√©mopathies et tumeurs solides
*** STRT 9.Anomalies g√©n√©tiques √† l‚Äô√©chelle du g√®ne
*** STRT 10. Principales techniques d‚Äôanalyses des anomalies g√©n√©tiques √† l‚Äô√©chelle du g√®ne
*** 11. S√©quencage haut d√©bit
*** 12. Conseil g√©n√©tique
*** 13. Examen de l‚Äôenfant
*** 14. H√©t√©rog√©n√©ite des maladies g√©n√©tiques
*** 15. DPN, DPI
*** 16. D√©pistage n√©onatal
*** 17. DPS
*** 18. Dispositions l√©gislatives
*** 19. Enjeux √©thiques
*** 20. Maladies mitochondriales
*** 21. Empreinte parentale
*** 22. Mutations dynamiques
*** 23. Oncog√©n√©tique
*** 24. Bases de donn√©es
*** 25. Perspectives th√©rapeutiques
*** 26. Pharmacog√©n√©tique
*** 27. G√©n√©tique des maladies complexes
*** 28. T21
*** 29. Mucoviscidose
*** 30. Xfragile
*** 31. Maladies rares
*** 32. M√©decine g√©nomique

** TODO Biologie cellulaire et mol√©culaire Dunod [22/209]
*** DONE Fiche 1
*** DONE Fiche 2
*** DONE Fiche 3
*** DONE Fiche 4
*** DONE Fiche 5
*** DONE Fiche 6
*** DONE Fiche 7
*** DONE Fiche 8
*** DONE Fiche 9
*** DONE Fiche 10
*** DONE Fiche 11
*** DONE Fiche 12
*** DONE Fiche 13
*** DONE Fiche 14
*** DONE Fiche 15
*** DONE Fiche 16
*** DONE Fiche 17
*** Fiche 18
*** Fiche 19
*** Fiche 20
*** Fiche 21
*** Fiche 22
*** Fiche 23
*** Fiche 24
*** Fiche 25
*** Fiche 26
*** Fiche 27
*** Fiche 28
*** DONE Fiche 29
*** Fiche 30
*** Fiche 31
*** Fiche 32
*** Fiche 33
*** Fiche 34
*** Fiche 35
*** Fiche 36
*** Fiche 37
*** Fiche 38
*** Fiche 39
*** Fiche 40
*** Fiche 41
*** Fiche 42
*** DONE Fiche 43
*** Fiche 44
*** DONE Fiche 45
*** DONE Fiche 46
*** DONE Fiche 47
*** Fiche 48
*** Fiche 49
*** Fiche 50
*** Fiche 51
*** Fiche 52
*** Fiche 53
*** Fiche 54
*** Fiche 55
*** Fiche 56
*** Fiche 57
*** Fiche 58
*** Fiche 59
*** Fiche 60
*** Fiche 61
*** Fiche 62
*** Fiche 63
*** Fiche 64
*** Fiche 65
*** Fiche 66
*** Fiche 67
*** Fiche 68
*** Fiche 69
*** Fiche 70
*** Fiche 71
*** Fiche 72
*** Fiche 73
*** Fiche 74
*** Fiche 75
*** Fiche 76
*** Fiche 77
*** Fiche 78
*** Fiche 79
*** Fiche 80
*** Fiche 81
*** Fiche 82
*** Fiche 83
*** Fiche 84
*** Fiche 85
*** Fiche 86
*** Fiche 87
*** Fiche 88
*** Fiche 89
*** Fiche 90
*** Fiche 91
*** Fiche 92
*** Fiche 93
*** Fiche 94
*** Fiche 95
*** Fiche 96
*** Fiche 97
*** Fiche 98
*** Fiche 99
*** Fiche 100
*** Fiche 101
*** Fiche 102
*** Fiche 103
*** Fiche 104
*** Fiche 105
*** Fiche 106
*** Fiche 107
*** Fiche 108
*** Fiche 109
*** Fiche 110
*** Fiche 111
*** Fiche 112
*** Fiche 113
*** Fiche 114
*** Fiche 115
*** Fiche 116
*** Fiche 117
*** Fiche 118
*** Fiche 119
*** Fiche 120
*** Fiche 121
*** Fiche 122
*** Fiche 123
*** Fiche 124
*** Fiche 125
*** Fiche 126
*** Fiche 127
*** Fiche 128
*** Fiche 129
*** Fiche 130
*** Fiche 131
*** Fiche 132
*** Fiche 133
*** Fiche 134
*** Fiche 135
*** Fiche 136
*** Fiche 137
*** Fiche 138
*** Fiche 139
*** Fiche 140
*** Fiche 141
*** Fiche 142
*** Fiche 143
*** Fiche 144
*** Fiche 145
*** Fiche 146
*** Fiche 147
*** Fiche 148
*** Fiche 149
*** Fiche 150
*** Fiche 151
*** Fiche 152
*** Fiche 153
*** Fiche 154
*** Fiche 155
*** Fiche 156
*** Fiche 157
*** Fiche 158
*** Fiche 159
*** Fiche 160
*** Fiche 161
*** Fiche 162
*** Fiche 163
*** Fiche 164
*** Fiche 165
*** Fiche 166
*** Fiche 167
*** Fiche 168
*** Fiche 169
*** Fiche 170
*** Fiche 171
*** Fiche 172
*** Fiche 173
*** Fiche 174
*** Fiche 175
*** Fiche 176
*** Fiche 177
*** Fiche 178
*** Fiche 179
*** Fiche 180
*** Fiche 181
*** Fiche 182
*** Fiche 183
*** Fiche 184
*** Fiche 185
*** Fiche 186
*** Fiche 187
*** Fiche 188
*** Fiche 189
*** Fiche 190
*** Fiche 191
*** Fiche 192
*** Fiche 193
*** Fiche 194
*** Fiche 195
*** Fiche 196
*** Fiche 197
*** Fiche 198
*** Fiche 199
*** Fiche 200
*** Fiche 201
*** Fiche 202
*** Fiche 203
*** Fiche 204
*** Fiche 205
*** Fiche 206
*** Fiche 207
*** Fiche 208
*** Fiche 209
** TODO Biologie chimie Dunod
* Divers
** TODO Photos famille
On utilise le drive commun qu'a fait Elise. Pour √©viter les soucis de connexion, on modifie juste le dossier partag√©:
https://drive.google.com/drive/folders/11wJ0E_KZv7I88wdv_ULHqd5KvWFfF0DF?usp=sharing_eip_m&invite=CPX0rho&ts=63ea1879

Autres drives :

    alexis: https://drive.proton.me/urls/PQ5M6TKVRM#q8yulEV8T5WG
    papa : https://www.mailo.com/mailo/docs/docs.php?s=IaK9Ajz8kwQJXNPnhJofRuDwyrNSZVy4&dir=mqn0f3%2bozZXc%2bwh4DeXwhVTY1Zz4zci5rZ4XcNHRmX7wPT0d9WG%2b0g%3d%3d&ea_encode=0

*** DONE Copier photos famille drive papa -> drive proton, drive yvain sur drive famille
CLOSED: [2023-02-12 Sun 23:17]
*** TODO Copier photos famille depuis drive yvain sur drive famille
*** TODO Trier photos sur drive yvain
* Voiture :voiture:
** Mazda 5
*** Notes
- Plaquettes : arri√®re gauche ok (50%) le <2022-09-03 Sat>
- besoin d'une cl√© 14 pour changer les plaquettes
*** TODO Changer courroie distribution
SCHEDULED: <2023-08-27 Sun>
√Ä faire au bout de 10ans, on attend l‚Äôan prochain

* Moto
:PROPERTIES:
:CATEGORY: moto
:END:
* Maison
:PROPERTIES:
:CATEGORY: maison
:END:
** DONE Saisie administrative taxe d'habitation
CLOSED: [2023-07-30 Sun 15:02]
/Entered on/ [2023-07-02 Sun 18:20]
D√©couverte <2023-07-02 Sun>. Virement 100.50‚Ç¨ fait.
Mail envoy√© ce jour
** TODO Vendre v√©lo
SCHEDULED: <2023-08-29 Tue>
/Entered on/ [2023-07-29 Sat 10:23]
** TODO Vendre frigo
SCHEDULED: <2023-10-17 Wed>
** TODO Vendre machine √† laver
SCHEDULED: <2023-10-17 Wed>
** DONE Photo √† √âric pour lit
CLOSED: [2023-07-30 Sun 19:07] SCHEDULED: <2023-07-30 Sun>
** DONE SMS annonce d√©m√©nagement
CLOSED: [2023-07-29 Sat 10:57] SCHEDULED: <2023-07-29 Sat>
/Entered on/ [2023-07-29 Sat 10:25]
** DONE Lettre recommand√©e annonce d√©m√©nagement
CLOSED: [2023-07-29 Sat 10:57] SCHEDULED: <2023-07-29 Sat>
#+category: maison
* Banque
:PROPERTIES:
:CATEGORY: banque
:END:
** WAIT Demande remboursement frais compte bancaire
/Entered on/ [2023-08-13 Sun 11:16]
* Programmation :cs:
** Gentoo :gentoo:
*** GURU :guru:
**** DONE Ebuild pour adapteur wifi TBW-108B
CLOSED: [2023-05-22 Mon 22:50]
Sur branche dev
**** DONE net-wireless/rtl8723bu: migration to linux-mod-r1.eclass
CLOSED: [2023-07-02 Sun 11:13] SCHEDULED: <2023-07-02 Sun>
**** DONE Ebuild hut
CLOSED: [2023-07-02 Sun 10:57]
sur dev
*** TODO Article nzbget sur wiki
/Entered on/ [2022-10-22 Sat 17:31]
*** KILL Gentoo package diagrams-graphviz :gentoo:haskell:
CLOSED: [2023-06-24 Sat 15:43] SCHEDULED: <2023-05-28 Sun>
/Entered on/ [2023-05-27 Sat 22:28]

** Learning Haskell :haskell:
*** [#A] [[https://www.reddit.com/r/haskell/comments/npxfba/comment/h084wwa/?utm_source=share&utm_medium=web2x&context=3][Reddit suggestion]]]
**** Learn Foundational building blocks
- [X] [[https://mmhaskell.com/monads/functors][Functor]]
- [X] [[https://mmhaskell.com/monads/applicatives][Applicatives]]
- [X] [[https://mmhaskell.com/monads/tutorial][Monads]]
- [X] [[https://mmhaskell.com/monads/reader-writer][Reader, writer]]
- [X] [[https://mmhaskell.com/monads/state][State]]
- [X] [[https://mmhaskell.com/monads/transformers][Transformers]]
- [ ] [[https://mmhaskell.com/monads/laws][Laws]]

**** Real-world example
***** STRT Look at the example
- [X] Database
- [ ] API
***** Relax for a few days and watch how interactive programs are being composed
***** Get back to the real-world example and make it a complete Cabal project.
***** [[https://mmhaskell.com/testing/test-driven-development][Testing]]
**** [#A] Best resource : [[https://downloads.haskell.org/~ghc/8.10.4/docs/html/users_guide/glasgow_exts.html#language-options][Language Reference]]
whenever you see an unknown language extension or a compilation flag, look it up in Language Reference and try to understand it. You don't have to fully understand them though, just read about them and keep them on your mind. One day they will begin to automatically click into a sound set of concepts.

Language Reference is one of the most underappreciated sources of information (it's almost universally overlooked in language communities - it was the case for Python, and I find it to be true for Haskell as well). You mentioned that you don't like REPL examples, and neither do I. Luckily, the User Guide/Reference has introductory sections for people like us. Once I knew how to compile a single file and to run it, the rest was just a matter of getting to know things by their name in a new ecosystem.

**** DONE Learn to compose things
When you already know how to compile and run single-module interactive console programs, it takes about a day to understand basics of Cabal, and about a week to learn about input parsing and output formatting. Do you need CLI args? Use optparse-applicative. Env vars? Use envy. JSON? Use aeson and a cheatsheet. Don't think about performance and/or API conventions, that's not what you should be concerned of at this point, as you are just learning to compose things together from individual parts.

**** Experiment with various libraires, read haskell planetarium
At this point you have enough knowledge to begin experimenting with various libraries and APIs. Learn how to use Hoogle, and read as much as you can/want on Haskell Planetarium.
*** KILL Learn Haskell for your greater good
   :PROPERTIES:
   :CUSTOM_ID: kill-learn-haskell-for-your-greater-good
   :END:

50%

*** HOLD [[books.org::Haskell%20Programming%20From%20First%20Principles][Haskell programming from first principles]]
*** GHC
**** GHC commentary
Notamment Ollie Charles's 24 days of GHC Extensions,
**** Lire [[https://www.aosabook.org/en/ghc.html]]
*** Vid√©os
**** STRT https://www.youtube.com/watch?v=re96UgMk6GQ
*** Articles historiques
1. [[https://watermark.silverchair.com/320098.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAsYwggLCBgkqhkiG9w0BBwagggKzMIICrwIBADCCAqgGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMHXfjdjwhGI2t4bLLAgEQgIICeQjZ-I8gmuaFqBktP4IOifHODtMAHcNF_LwRYyq7NswQ7vT6LJho9P_junCAORLGMV9dgq9JMePH2PFKNxXxrEP1VY7rIDG0gzoeObSkgMDn4MXalrIxD3ejY8vsGYy6vce8Kh70J_UJ8RamO1l3BNNUzy2W6VRaa_cMQr_ekdwcz0oihz0BVKn_bgm_8DjiiPhzj8uU9flVhi13t_oIFA6b3At2QMmPe7Z9OyfLkXivKkmKKNoHwSS7AnTIYAKCO383e4kG6NzZ_elai-XMAJs2Nk0vcgaltld1KeaW3269104DdIlFGevJUVNgwE_4LIheSYRZr9Gr0yRR6TROxdsyxrmgQ22Pzxxpnl8-KdjkW6aRSCKNk_yb5hYcPoRa3ldc5yPV15j8i4t9Mv4U_mBwmIRtMIKPdEHeMvcRx6c8_8uT4RV2esuOPfZlA05bzBgJhMS87M8myxisH-exkTMkm58o6nzHf1lGxzn_JS1VSHbhJCUl82ubzzOWjvl3QJM_vv805XTbn_G-fcRi0d9EQIRTqoObWVFyXW-pz16bWoZPZnBQ1gOmc3hPTGBMZjFR6p9VEAO7bKcK8o0yQDjVWEELNwfAAHc-oF_wLiEjXDNBoUttghgQzzvymKY_jSZhcU8TraVu2i551fpuDNEjSJd0qY5Rg3J6eWU550nJmnoWmX6o7KGiYp0vVMfOoFYXJ1trZWSGoRhDQP2LOLIOt3t2idlj6kV_MoCY3BRnkbxf4XIH7gLJf6Dky6hXFbTU8Fjsn8XHBeKSmaAYJ-sbmGB_BdZO8hHyvHvPv0lTtGcSuKywoJhMbblXRzyuacj_6mZQl5j3tAWhy][Why functional programming matters]]
   Tr√®s lisible
2. [[https://dl.acm.org/doi/pdf/10.1145/91556.91592][Comprehending monads]]
   Introduction du concept
3. [[https://dl.acm.org/doi/pdf/10.1145/158511.158524][Imperative functional programming]]
   Application des monads poru r√©soudre le probl√®me IO
